19. ライソゾーム病 Lysosomal storage disease Clinical trials / Disease details
臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04787887 (ClinicalTrials.gov) | January 29, 2020 | 4/3/2021 | A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers | A Randomized, Double-blind, 2-treatment, 2-period, Crossover Phase I Study to Compare the PK, Safety and Tolerability of 60 IU/kg of Abcertin, and EU-sourced Cerezyme® in Healthy Volunteers Following a Single Intravenous Administration | Gaucher Disease | Drug: Abcertin;Drug: EU-sourced Cerezyme | ISU Abxis Co., Ltd. | NULL | Completed | 18 Years | 45 Years | All | 42 | Phase 1 | Australia |